vaccineinduc
antibodi
prevent
case
felin
infecti
periton
viru
aggrav
infect
coronavirus
investig
whether
recombin
nativ
fulllength
sprotein
trimer
trispik
sever
acut
respiratori
syndrom
coronaviru
sarscov
abl
elicit
neutral
protect
immun
respons
anim
analyz
capac
anti
antibodi
mediat
antibodydepend
enhanc
ade
viru
entri
vitro
enhanc
replic
vivo
sarscovspecif
serum
mucos
immunoglobulin
readili
detect
immun
anim
serum
igg
block
bind
sprotein
receptor
neutral
sarscov
infect
vitro
entri
human
b
cell
line
occur
fashion
indic
ade
viru
entri
novel
cell
entri
mechan
sarscov
vaccin
anim
show
sign
enhanc
lung
patholog
hepat
viral
load
undetect
greatli
reduc
lung
follow
challeng
sarscov
altogeth
result
indic
recombin
trimer
protein
abl
elicit
efficaci
protect
immun
respons
vivo
warrant
concern
safeti
evalu
human
vaccin
sarscov
coronaviru
infect
human
respiratori
tract
occur
frequent
infect
account
common
cold
human
recent
identifi
human
coronaviru
associ
acut
respiratori
distress
syndrom
pneumonia
coronaviru
infect
mild
selflimit
infect
sever
acut
respiratori
syndrom
coronaviru
sarscov
result
high
mortal
morbid
current
vaccin
avail
human
coronaviru
infect
viral
surfac
spike
glycoprotein
key
target
protect
neutral
antibodi
coronavirus
sprotein
kda
highli
glycosyl
trimer
classi
fusion
protein
respons
receptor
bind
virusmembran
fusion
tissu
tropism
angiotensin
convert
enzym
identifi
function
receptor
viru
entri
suscept
target
cell
ctype
lectin
lsign
also
shown
mediat
viru
uptak
smediat
viral
entri
occur
phdepend
manner
inhibit
sspecif
sera
neutral
antibodi
broadli
elicit
patient
sar
passiv
transfer
sspecif
antibodi
includ
monoclon
antibodi
direct
receptorbind
domain
rbd
anim
confer
protect
sarscov
challeng
indic
humor
immun
respons
alon
protect
sarscov
sar
vaccin
candid
induc
strong
protect
immun
infect
persontoperson
transmiss
requir
humor
immun
respons
system
mucos
level
absenc
immunopatholog
differ
vaccin
candid
explor
sar
includ
dna
modifi
vaccinia
viru
ankara
mva
subunit
vaccin
inactiv
viru
vaccin
shown
induc
neutral
protect
respons
protect
achiev
mous
recombin
mva
viru
express
protein
vaccin
differ
mva
construct
fail
elicit
sustain
serum
neutral
antibodi
titer
sarscov
ferret
subsequ
challeng
sarscov
associ
hepat
vitro
data
also
demonstr
anti
immun
respons
enhanc
sarscov
entri
target
cell
yang
colleagu
show
entri
sarscov
pseudotyp
virus
express
palm
civet
sprotein
human
renal
epitheli
celllin
enhanc
human
sspecif
neutral
antibodi
vitro
detect
facilit
antibodi
correl
diseas
enhanc
felin
infecti
periton
virusinfect
cat
fipv
shown
vaccineinduc
anti
antibodi
macrophageexpress
fc
receptor
fcr
key
factor
antibodydepend
enhanc
ade
cat
anim
model
sar
use
evalu
neutral
enhanc
capac
antibodi
vivo
sever
anim
model
propos
sar
includ
mice
ferret
hamster
rhesu
cynomologu
macaqu
hamster
interest
small
anim
model
reproduc
sever
patholog
featur
human
sar
includ
high
titer
replic
sarscov
lung
nasal
turbin
mark
lung
patholog
includ
cellular
necrosi
inflammatori
cell
infiltr
present
studi
analyz
immun
respons
recombin
nativ
fulllength
protein
trimer
sarscov
neutral
enhanc
activ
could
detect
sera
immun
anim
human
convalesc
sar
patient
sera
vitro
challeng
experi
hamster
indic
complet
protect
absenc
diseas
enhanc
vivo
human
raji
b
cell
cultur
describ
previous
murin
macrophag
cell
line
cultur
c
co
dulbecco
modifi
eagl
medium
supplement
fb
u
penicillinml
g
streptomycinml
optim
dna
semliki
forest
viru
express
vector
encod
sarscov
sprotein
fuse
ctermin
flagsequ
describ
previous
protein
product
bhk
cell
cultur
presenc
absenc
cycloheximid
gml
ad
h
preharvest
fourteen
hour
postinfectiontransfect
cell
lyse
mm
trishcl
ph
mm
nacl
mm
edta
triton
incub
min
ice
collect
lysat
vortex
incub
anoth
min
ice
prior
centrifug
rpm
min
recombin
sprotein
immunopurifi
use
antiflag
mabcoat
agaros
bead
sigma
describ
previous
quantiti
qualiti
recombin
sprotein
assess
sdspage
western
blot
use
bapflag
protein
microbsa
method
standard
protein
quantif
mous
sera
dilut
prior
western
blot
analysi
immun
complex
detect
hrpconjug
antimous
igg
h
l
zyme
follow
visual
band
xray
film
kodak
use
chemiluminesc
amersham
bioscienc
balbc
mice
week
old
n
per
group
immun
intraperiton
ip
g
purifi
trispik
trispik
mg
aluminium
hydroxid
gel
alum
day
anim
control
group
receiv
pb
mg
alum
day
blood
sampl
collect
saphen
vein
bleed
indic
time
point
accord
local
guidelin
sera
prepar
heatinactiv
fecal
sampl
nasal
lavag
prepar
describ
previous
hrpconjug
antimous
igg
h
l
iga
zyme
use
detect
exist
igg
iga
antibodi
trispik
immun
mice
fecal
nasal
lavag
sampl
absenc
blood
contamin
confirm
use
hemascreen
occult
blood
detect
kit
stanbio
laboratori
antibodi
fecal
sampl
use
final
dilut
nasal
lavag
sampl
dilut
western
blot
analysi
six
eight
week
old
femal
golden
syrian
hamster
n
per
group
immun
subcutan
sc
g
purifi
trispik
mg
alum
hkupasteur
research
centr
hong
kong
china
parallel
experi
hamster
perform
niaid
nih
bethesda
maryland
immun
g
purifi
trispik
mg
alum
recombin
sprotein
express
cell
detach
mm
edta
incub
min
c
dilut
hamster
sera
wash
fix
pfa
min
c
label
fitcconjug
goat
antisyrian
hamster
igg
santa
cruz
biotechnolog
min
c
cell
analyz
flow
cytomet
facscalibur
bd
step
block
normal
goat
serum
zyme
fluoresc
valu
express
mean
fluoresc
intens
mfi
bind
assay
perform
incub
solubl
receptor
sprotein
coat
agaros
bead
describ
previous
inhibit
bind
analysi
proteinco
bead
preincub
sera
h
c
incub
solubl
bead
wash
four
time
lysi
buffer
mm
trishcl
mm
nacl
mm
edta
triton
prior
sdspage
western
blot
analysi
neutral
assay
carri
cell
use
sarscov
strain
depart
microbiolog
hku
follow
one
hundr
tcid
sarscov
incub
h
c
serial
dilut
heatinactiv
mous
sera
quadrupl
viru
antibodi
mix
ad
cell
plate
plate
incub
c
microscop
examin
cytopath
effect
cpe
incub
neutral
titer
calcul
reed
muench
formula
express
reciproc
serum
dilut
neutral
cpe
well
recombin
sarscovpp
lentivir
vector
express
luciferas
report
gene
produc
cell
describ
previous
use
g
plasmid
r
e
pro
g
plasmid
pcdnasflag
encod
codonoptim
sarscov
protein
ade
assay
l
serial
dilut
heatinactiv
murin
hamster
sera
incub
h
c
l
pseudoviru
ng
fifti
microlit
raji
cell
cellml
previous
wash
three
time
serumfre
rpmi
ad
antibodysarscovpp
mixtur
plate
adsorpt
h
c
l
rpmi
contain
fc
ad
medium
renew
h
later
incub
addit
h
wash
pb
lyse
luciferas
activ
measur
sec
microbeta
jet
counter
perkin
elmer
accord
instruct
provid
supplier
promega
ade
block
assay
raji
cell
preincub
min
c
gml
murin
monoclon
antibodi
direct
human
bd
pharmingen
goat
polyclon
antibodi
direct
human
r
system
prior
infect
sarscovpp
day
day
follow
last
immun
anesthet
hamster
receiv
l
tcid
sarscov
strain
urbani
intranas
tabl
hamster
euthanat
lethal
intraperiton
inject
sodium
pentobarbit
lhamster
day
follow
challeng
peak
viru
replic
pneumon
anticip
day
post
challeng
look
possibl
late
chang
histopatholog
sixteen
forti
eight
sarscovinocul
hamster
sacrif
day
postchalleng
lung
harvest
process
viral
titrat
group
sarscovinocul
hamster
sacrif
day
postchalleng
lung
liver
harvest
process
patholog
studi
tissu
sampl
homogen
viru
titer
determin
cell
monolay
describ
previous
four
hamster
per
group
immun
challeng
describ
sacrif
day
postchalleng
addit
four
hamster
per
group
one
addit
hamster
gdose
group
sacrif
day
follow
challeng
lung
evalu
pneumon
consolid
previous
describ
colorimetr
immunoalkalin
phosphatas
ihc
method
use
identifi
sarscov
antigen
hamster
serum
sampl
analyz
level
aspart
aminotransferas
ast
alanin
aminotransferas
alt
alkalin
phosphatas
alp
gammaglutamyl
transferas
ggt
blood
urea
nitrogen
bun
total
bilirubin
use
blood
chemistri
analyz
analyt
medtec
lab
fulllength
codonoptim
sarscov
sprotein
fuse
ctermin
flag
purifi
singlestep
immunoaffin
protocol
puriti
averag
yield
g
pure
sprotein
per
cell
ie
mgl
fig
analysi
appar
molecular
weight
protein
sdspage
western
blot
nonreduc
condit
reveal
predomin
trimer
natur
antigen
fig
lane
trimer
dissoci
monom
protein
heatdenatur
presenc
sd
indic
monom
associ
noncoval
fig
lane
higher
molecular
weight
dttsensit
aggreg
observ
protein
heat
denatur
prior
sdspage
fig
lane
expect
trimer
aggreg
dissoci
complet
monom
heatdenatur
sd
dtt
fig
lane
monom
deriv
sdsheatdenatur
trimer
slightli
greater
electrophoret
mobil
monom
deriv
sdsheatdtt
denatur
trimer
indic
intramolecular
disulfid
bond
lead
compact
three
dimension
conform
spike
monom
trimer
monomer
sprotein
frequent
migrat
doublet
fig
repres
highmannos
glycoform
protein
resid
er
time
lysi
glycoform
protein
acquir
complex
nglycan
mediangolgi
trispik
nativ
antigen
shown
reactiv
sera
convalesc
sar
patient
western
blot
fac
data
shown
nativ
fold
underscor
specif
bind
trispik
protein
solubl
receptor
fig
lane
altogeth
result
strongli
argu
purifi
trispik
molecul
mimic
nativ
trimer
sprotein
virion
surfac
immunogen
trispik
assess
immun
three
differ
dose
without
adjuv
alum
mice
hamster
fig
immun
mice
trispik
alon
induc
low
level
anti
antibodi
fig
howev
singl
subsequ
inject
trispik
induc
detect
level
antibodi
sprotein
fig
could
boost
third
inject
fig
sera
reactiv
mono
diand
trimer
sprotein
carri
either
highmannos
complex
nglycosyl
analysi
individ
western
blot
analysi
pool
sera
immun
mice
without
alum
adjuv
sera
collect
use
dilut
sflag
separ
condit
allow
simultan
detect
mono
di
trimer
sprotein
sar
patient
serum
sar
rabbit
serum
monoclon
antibodi
flag
peptid
use
control
flagtag
bacteri
alkalin
phosphatas
bapflag
use
assess
presenc
antibodi
flag
tag
immun
complex
detect
hrpconjug
goat
antimous
human
rabbit
igg
polyclon
antibodi
size
molecular
weight
marker
indic
right
b
reactiv
immun
sera
pool
immun
hamster
live
cell
express
sprotein
plasma
membran
use
fac
analysi
valu
express
mean
standard
deviat
c
effect
alum
adjuv
longev
neutral
respons
mous
sera
sarscov
determin
cell
valu
express
mean
standard
deviat
dose
effect
trispik
immun
alum
adjuv
neutral
respons
sarscov
hamster
determin
cell
valu
express
mean
standard
deviat
e
inhibit
sprotein
bind
sera
immun
mice
sprotein
coat
bead
preincub
sera
prior
incub
solubl
detect
receptor
perform
polyclon
goatanti
human
antibodi
bapflag
coat
bead
use
control
ual
serum
sampl
confirm
homogen
antibodi
respons
individu
mice
data
shown
trispik
use
combin
alum
adjuv
fig
similar
respons
observ
except
level
anti
igg
slightli
higher
second
inject
fig
third
inject
increas
anti
serum
antibodi
level
fig
neither
trispik
trispik
alum
adjuv
immun
induc
antibodi
direct
flag
peptid
fig
lower
panel
next
step
analyz
dose
respons
booster
immun
effect
hamster
immun
g
trispik
plu
alum
facscan
first
immun
three
dose
result
moder
anti
antibodi
respons
fig
second
inject
strongli
increas
anti
antibodi
level
fig
increas
anti
antibodi
level
seen
third
inject
fig
signific
dosedepend
antibodi
respons
g
trispik
plu
alum
immun
seem
induc
maximum
antibodi
respons
hamster
model
analysi
individu
serum
sampl
confirm
homogen
antibodi
respons
individu
hamster
data
shown
altogeth
result
indic
optim
anti
antibodi
respons
might
requir
two
dose
trispik
g
immun
alum
adjuv
next
evalu
neutral
activ
sera
trispik
vaccin
mice
serial
dilut
sera
test
neutral
activ
cpe
induc
sarscov
replic
cell
neutral
tcid
inject
trispik
alum
adjuv
induc
higher
neutral
titer
compar
trispik
alon
fig
antibodi
titer
trispik
alum
immun
anim
remain
high
level
day
neutral
titer
drop
rapidli
day
day
anim
inject
trispik
alon
subsequ
doserespons
experi
perform
hamster
sera
hamster
immun
least
two
dose
low
g
effect
neutral
tcid
sarscov
cell
fig
boost
effect
third
inject
limit
three
dose
maximum
antibodi
level
obtain
anim
immun
g
next
investig
mechan
neutral
analyz
capac
sera
block
interact
immunopurifi
trispik
coat
agaros
bead
purifi
solubl
human
sarscov
entri
receptor
fig
show
sera
trispik
alum
immun
mice
lane
control
anim
lane
neutral
sprotein
bind
receptor
result
suggest
inhibit
receptor
bind
key
mechan
neutral
trispik
immun
anim
detect
sarscov
intestin
tissu
fatal
sar
case
indic
gastrointestin
tract
anoth
target
sarscov
infect
henc
vaccin
candid
ideal
induc
protect
respons
mucos
site
previou
studi
suggest
induct
igg
respons
serum
system
respons
iga
respons
stool
mucos
respons
sampl
yersinia
pesti
use
intraperiton
immun
address
question
antibodi
prepar
fecal
sampl
immun
anim
occult
blood
detect
show
absenc
blood
contamin
data
shown
indic
sampl
contamin
serum
antibodi
western
blot
use
antibodi
isol
fecal
sampl
reveal
mucos
igg
iga
induc
trispik
plu
alum
trispik
alon
fig
antibodi
abl
neutral
sarscov
infect
cell
fig
altogeth
conclud
trispik
plu
alum
immun
induc
antigenspecif
igg
iga
gastrointestin
tract
mice
also
analyz
presenc
anti
antibodi
nasal
lavag
sampl
occult
blood
detect
indic
absenc
blood
contamin
sampl
western
blot
analysi
use
antibodi
isol
nasal
lavag
reveal
induct
mucos
igg
respons
trispik
plu
alum
immun
trispik
immun
alon
fig
unabl
detect
iga
respons
either
group
anti
antibodi
nasal
lavag
sampl
neutral
sarscov
fig
studi
requir
address
respect
role
iga
igg
neutral
activ
epitop
specif
antibodi
titer
neutral
mechan
investig
whether
vaccineinduc
anti
antibodi
trispik
could
mediat
ade
sarscov
entri
fcr
express
cell
line
sar
pseudotyp
particl
sarscovpp
gener
studi
recom
binant
virus
encod
luciferas
report
gene
express
sarscov
spike
protein
virion
surfac
shown
faith
mimic
sarscov
entri
process
infect
cell
sarscovpp
presenc
absenc
heatinactiv
serum
trispik
immun
mice
hamster
well
sera
ten
convalesc
sar
patient
transduct
fcrneg
cell
sarscovpp
reduc
dosedepend
manner
pseudoviru
preincub
sspecif
antisera
fig
c
sarscovpp
preincub
heatinactiv
sspecif
mous
hamster
sera
dosedepend
enhanc
raji
b
daudi
cell
transduct
observ
fig
background
level
transduct
detect
absenc
serum
presenc
sera
control
group
raji
b
cell
preincub
monoclon
antibodi
mab
human
sarscovpp
transduct
reduc
background
lev
el
demonstr
pseudoviru
entri
depend
fig
furthermor
ade
could
abrog
preincub
pseudovirusantibodi
mix
protein
g
demonstr
process
mediat
fc
portion
antibodi
data
shown
interestingli
mab
block
transduct
cell
sarscovpp
raji
b
cell
sarscovppantibodi
complex
indic
mediat
viru
entri
requir
viruscel
membran
fusion
fig
low
level
sarscovpp
transduct
observ
murin
macrophag
cell
line
despit
presenc
receptor
ade
limit
vaccineinduc
anti
sera
mice
hamster
eight
ten
sera
convalesc
sar
patient
also
show
enhanc
raji
b
cell
transduct
despit
capac
sera
neutral
viru
entri
cell
data
shown
result
demonstr
sspecif
antibodi
induc
shift
cell
tropism
sarscov
toward
human
express
cell
antibodyand
viru
entri
fusion
novel
mechan
sarscov
enter
target
cell
syrian
golden
hamster
immun
time
biweekli
interv
g
g
g
trispik
plu
alum
challeng
intranas
tcid
hamster
sarscov
hamster
receiv
trispik
vaccin
significantli
protect
sarscov
challeng
compar
mock
immun
control
fig
complet
protect
observ
follow
three
dose
g
mean
viral
titer
limit
detect
partial
protect
observ
hamster
receiv
lowest
dose
half
hamster
receiv
three
dose
g
trispik
vaccin
show
complet
protect
challeng
mean
viral
titer
group
tcid
g
tissu
seventyf
percent
hamster
receiv
three
dose
g
trispik
vaccin
show
complet
protect
challeng
one
hamster
group
viral
titer
limit
detect
tcidsog
tissu
comparison
four
mock
immun
hamster
similar
high
titer
sarscov
present
mean
viral
titer
tcidsog
tissu
pattern
consist
elev
liver
enzym
observ
group
follow
immun
sarscov
challeng
data
shown
five
day
follow
sarscov
challeng
mock
immun
hamster
sever
pneumon
consolid
comparison
trispik
immun
hamster
mild
moder
sever
pneumon
none
pulmonari
consolid
data
indic
regardless
dose
administ
vaccin
significantli
protect
occurr
sever
pneumon
follow
sarscov
challeng
contrast
previous
publish
data
pneumon
consolid
complet
clear
day
postchalleng
moder
sever
pneumon
observ
day
postchalleng
mock
immun
hamster
trispik
immun
hamster
day
postchalleng
pneumon
complet
clear
reduc
mild
moder
level
variat
observ
previous
report
observ
time
resolut
pneumon
like
due
chang
tissu
process
lung
inflat
formalin
studi
previou
report
nevertheless
consist
previous
report
data
day
challeng
pulmonari
consolid
absent
group
includ
mock
immun
control
histopatholog
analys
liver
day
postchalleng
reveal
rare
foci
hepat
cellular
necrosi
foci
observ
mock
immun
trispik
immun
hamster
postchalleng
show
correl
either
prechalleng
neutral
antibodi
titer
liver
enzym
level
preor
postchalleng
furthermor
sarscov
antigen
detect
immunohistochem
stain
current
licens
vaccin
human
coronaviru
vaccin
anim
coronavirus
success
gener
eg
transmiss
gastroenter
viru
tgev
howev
develop
vaccin
fipv
proven
difficult
due
immun
enhanc
diseas
vaccin
cat
receptor
bind
viral
envelop
glycoprotein
prime
target
neutral
antibodi
hypothes
sarscov
envelop
nativ
trimer
conform
would
optim
induct
conformationdepend
neutral
antibodi
target
multipl
epitop
fulllength
coronaviru
spike
glycoprotein
intact
transmembran
domain
previous
shown
assembl
rosett
gener
highli
immunogen
envelop
lipid
sphere
biochem
character
sprotein
immunogen
show
purifi
recombin
protein
migrat
sdspage
appar
molecular
weight
kda
suggest
trimer
correctli
fold
protein
complexglycosyl
noncoval
link
homotrimer
glycoprotein
cleav
intracellular
proteas
exit
cell
surfac
result
agreement
data
obtain
other
sar
coronavirus
immunopurifi
prepar
fulllength
trimer
trispik
contain
correctli
fold
protein
also
mannosyl
high
molecular
weight
form
like
er
retain
protein
yet
correctli
fold
degrad
inde
highmannos
form
purg
er
evidenc
pulsechas
experi
treatment
express
cell
translat
inhibitor
cycloheximid
correct
fold
nativ
conform
trispik
confirm
bind
solubl
receptor
preliminari
result
obtain
two
solubl
form
sprotein
ectodomain
secd
show
secd
migrat
appar
molecular
weight
trimer
kda
consist
model
trimer
domain
locat
within
membran
proxim
domain
migrat
appar
molecular
weight
monom
data
shown
find
agreement
previou
report
show
coronaviru
mhv
tgev
protein
trimer
immun
studi
mice
hamster
demonstr
trispik
highli
immunogen
induc
longlast
neutral
respons
remain
stabl
month
neutral
titer
immunogen
administ
alum
adjuv
licens
use
human
mucos
immun
provid
firstlin
defens
mechan
viral
infect
respiratori
tract
intestin
lumen
sarscov
replic
result
show
neutral
igg
iga
respons
induc
immun
protein
adjuv
alum
induct
anti
iga
absent
nasal
lavag
sampl
studi
might
critic
improv
neutral
activ
sever
studi
previous
point
toward
receptor
bind
domain
rbd
within
key
target
neutral
antibodi
human
mab
nonimmun
human
antibodi
librari
describ
block
associ
sprotein
experi
sera
collect
secd
immun
anim
also
neutral
sarscov
unpublish
data
suggest
key
neutral
epitop
locat
domain
correct
conform
monom
alon
suffici
achiev
neutral
respons
data
show
purifi
protein
vaccin
induc
block
antibodi
high
effici
inde
neutral
sera
vaccin
mice
prevent
trispik
bind
solubl
human
receptor
indic
rbd
access
antibodi
suggest
receptor
bind
inhibit
key
mechan
viru
neutral
trispik
immun
anim
howev
block
receptor
bind
might
sole
mechan
viru
neutral
neutral
antibodi
put
protein
suggest
antibodi
also
block
post
bind
step
eg
conform
transit
subunit
requir
membran
fusion
antibodydepend
enhanc
ade
infect
describ
sever
virus
eg
dengu
viru
human
immunodefici
viru
ebola
viru
fipv
ade
occur
virusantibodi
complex
interact
fcr
complement
trigger
viru
uptak
altern
antibodi
induc
conform
chang
envelop
glycoprotein
requir
viruscel
membran
fusion
antibodydepend
conform
chang
previous
report
civet
cat
strain
sarscov
show
enhanc
entri
human
renal
epitheli
celllin
presenc
human
monoclon
antibodi
human
strain
sarscov
spike
could
exclud
mechan
enhanc
sera
trispik
vaccin
mice
neutral
rather
enhanc
viru
infect
cell
howev
observ
sera
trispik
vaccin
mice
hamster
show
fold
increas
viru
entri
posit
human
b
cell
ade
still
observ
complement
inactiv
heat
treatment
sera
could
abrog
protein
g
antibodi
demonstr
ade
mediat
fc
region
antibodi
receptor
interestingli
genotyp
human
receptor
recent
correl
sever
diseas
sar
patient
result
show
antibodi
reduc
transduct
pseudovirusantibodi
complex
indic
spikemedi
viru
cell
entri
membran
fusion
occur
mechan
togeth
previous
describ
data
result
suggest
pseudovirusantibodi
complex
might
endocytos
via
follow
proteas
cleavag
endosom
membran
fusion
low
ph
endosom
compart
ade
fipv
model
link
specif
enhanc
nonneutr
epitop
enhanc
nonneutr
antibodi
analysi
monoclon
antibodi
provid
evid
whether
antibodi
subclass
specif
epitop
involv
enhanc
mechan
interestingli
observ
enhanc
phenotyp
human
b
cell
line
mous
macrophag
despit
presenc
reason
unclear
respect
role
activ
inhibit
human
ident
extracellular
heterolog
intracellular
domain
signal
capac
might
play
role
ade
sarscov
entri
restrict
vaccineinduc
anti
antibodi
also
observ
sar
patient
sera
eight
ten
sera
capabl
neutral
infect
cell
found
enhanc
transduct
b
cell
line
b
cell
shown
occasion
infect
patient
sar
howev
enhanc
viral
entri
b
cell
could
profound
effect
pathogenesi
even
ensu
viral
replic
cell
type
abort
vaccineinduc
antibodi
enhanc
entri
viru
could
increas
frequenc
b
cell
infect
vaccin
subject
alter
diseas
subsequ
exposur
sarscov
vaccinemedi
protect
sarscov
infect
mice
demonstr
use
differ
vaccin
approach
howev
mice
replic
sarscov
high
titer
show
pronounc
patholog
lung
contrari
ferret
cynomolgu
macaqu
hamster
shown
support
high
titer
replic
sarscov
respiratori
tract
associ
pneumon
order
assess
respect
role
neutral
ade
vivo
perform
sarscov
challeng
experi
hamster
vaccin
three
dose
g
protein
alum
adjuv
vaccin
group
show
signific
decreas
viral
load
day
post
challeng
least
four
order
magnitud
without
sign
enhanc
lung
patholog
rare
foci
hepatocyt
necrosi
observ
hamster
correl
prechalleng
neutral
antibodi
titer
liver
enzym
level
preor
postchalleng
immunohistochem
detect
sarscov
antigen
suggest
hepat
cellular
necrosi
unrel
sarscov
immun
infect
syrian
golden
hamster
contrast
report
hepat
day
follow
challeng
sarscov
ferret
vaccin
poorli
immunogen
recombin
mva
vaccin
express
sarscov
spike
protein
altogeth
result
indic
recombin
trimer
protein
abl
elicit
protect
immun
respons
vivo
observ
enhanc
entri
b
cell
vitro
shown
vivo
correl
would
warrant
concern
safeti
evalu
human
vaccin
sarscov
